Skip to main content
Log in

Phase I study of paclitaxel administered by ten-day continuous infusion

  • Published:
Investigational New Drugs Aims and scope Submit manuscript

Abstract

Purpose: Pre-clinical data have suggested that prolonged exposure to paclitaxel enhances its cytotoxicity, but various clinical trials utilizing long-term infusions of paclitaxel have been limited by unacceptable hematologic toxicity, most notably significant neutropenia. A phase I study of paclitaxel administered over 10 days, was performed to evaluate the hematologic and non-hematologic toxicities as well as to determine the maximum-tolerated dose for the 10-day infusion duration.

Patients and methods: Twenty-nine solid tumor patients (predominantly non-small cell lung cancer and head and neck cancer) were treated with paclitaxel at doses ranging from 5 mg/m2/day to 25 mg/m2/day administered as a 10-day continuous infusion via a pump every 21 days. Dose escalation was permitted within individual patients. Dose-limiting toxicity (DLT) was defined as grade 3 or 4 non-hematologic toxicity, ANC ≤ 500 or platelet count ≤ 25,000 for ≥ 7 days or febrile neutropenia. The maximum tolerated dose (MTD) was defined as the highest dose level at which less than two out of six patients developed DLT. All of the patients had received prior chemotherapy; approximately two-thirds had received prior radiation as well. All patients received standard pre-medications for paclitaxel, including anti-histamines and corticosteroids. Prophylactic granulocyte colony-stimulating factor (G-CSF) was not used.

Results: A total of 110 courses of paclitaxel were administered to 29 patients. The incidence of hematologic and non-hematologic toxicity was quite low among the patients treated at dose levels below 17 mg/m2/day. At higher doses, non-hematologic toxicities including arthralgias, myalgias, fatigue, nausea, stomatitis, and peripheral neuropathy were seen, although nearly all of the toxicities were less than grade 3 (NCI toxicity criteria). Hematologic toxicity mostly consisted of neutropenia and was more common at dose levels of 17 mg/m2/day or higher. Nevertheless, even at the highest dose levels (21 mg/m2/day and 25 mg/m2/day) grade 3 or 4 neutropenia occurred in only 50% of patients. Dose-limiting hematologic toxicity occurred in 2 of 4 patients treated at the 25 mg/m2/day dose level.

Conclusion: Paclitaxel can be safely administered as a 10-day infusion. The MTD for this schedule is 210 mg/m2. Unlike the 96-hour paclitaxel infusions, dose-reduction for myelosuppression may not be necessary because the MTD of paclitaxel when administered over a 10-day infusion is similar to the MTD of paclitaxel when infused over 3 or 24 hours.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

  1. Rowinsky EK, Donehower RC: Paclitaxel (Taxol). New Eng J Med 332: 1004-1014, 1995

    Google Scholar 

  2. Schiff PB, Horwitz SE: Taxol stabilizes microtubules in mouse fibroblast cells. Proc Natl Acad Sci USA 77: 1561-1565, 1980

    Google Scholar 

  3. Holmes FA, Walters RS, Theriault RL, Valero V, Booser DJ, Faschini G, Buzdar AU, Gibbs HR, Frye D, Hortobagy G: Phase Il trial of taxol, an active drug in the treatment of metastatic breast cancer. J Natl Cancer Inst 83: 1797-1805, 1991

    Google Scholar 

  4. Reichman BS, Seidman AD, Crown JP, Heelan R, Hakes TB, Lebwohl DE, Gilewski TA, Surbone A, Currie V, Hudis CA: Paclitaxel and recombinant human granulocyte colony-stimulating factor as initial chemotherapy for metastatic breast cancer. J Clin Oncol 11: 1943-1951, 1993

    Google Scholar 

  5. McGuire WP, Rowinsky EK, Rosenshein NE: Taxol: a unique anti-neoplastic agent with significant activity in advanced ovarian epithelial neoplasms. Ann Intern Med 111: 273279, 1989

    Google Scholar 

  6. Thigpen JT, Blessing JA, Ball H, Hummel SJ, Barrett RJ: Phase II trial of paclitaxel in patients with progressive ovarian carcinoma after platinum-based chemotherapy: a Gynecological Oncology Group study. J Clin Oncol 12: 1748-1753, 1994

    Google Scholar 

  7. Forastiere AA, Newberg D, Taylor SG, DeConti R, Adams G: Phase II evaluation of taxol in advanced head and neck cancer: an Eastern Cooperative Oncology Group trial. J Natl Cancer Inst monograph 15: 181-184, 1993

    Google Scholar 

  8. Shin DM, Glisson B, Khuri F, Ginsberg L, Papadimitrakopoulou V, Lee J, Lawhorn K, Gillenwater A, Ang K, Clayman G, Callender D, Hong WK, Lippman S: Phase II trial of paclitaxel, ifosfamide, and cisplatin in patients with recurrent or metastatic squamous cell carcinoma of the head and neck. J Clin Oncol 16: 1325-1330, 1998

    Google Scholar 

  9. Murphy WK, Fossella FV, Winn RJ, Shin D, Hynes HC, Gross HM, Davilla E, Leimert J, Dhingra H, Raber MN: Phase II study of taxol in patients with untreated non-small-cell lung cancer. J Natl Cancer Inst 85: 384-388, 1993

    Google Scholar 

  10. Chang AY, Kim K, Glick J, Anderson T, Karp D, Johnson D: Phase II study of taxol, merbarone, and piroxantron in stage IV non-small-cell lung cancer: the Eastern Cooperative Oncology Group Results. J Natl Cancer Inst 85: 388-396, 1993

    Google Scholar 

  11. Wilson WH, Berg SL, Bryant G, Wittes RE, Bates S, Fojo A, Steinberg SM, Goldspiel BR, Herdt J, O'shaughnessy J: Paclitaxel in doxorubicin-refractory or mitoxantrone-refractory breast cancer: A phase I/II trial of 96-hour infusion. J Clin Oncol 12: 1621-1629, 1994

    Google Scholar 

  12. Spriggs DR, Tondini C: Taxol administered as a 120 hour infusion. Invest New Drugs 10: 275-278, 1992

    Google Scholar 

  13. Skubitz KM: A phase I study of ambulatory continuous infusion paclitaxel, abstract. Proc Am Assoc Cancer Res 37: 1149, 1996

    Google Scholar 

  14. Riseberg D, Cowan K, Zujewski J, Tolcher A, Denicoff A, Noone M, Barnes C, Goldspiel B, O'shaughnessy J: Phase I study of a 14-day paclitaxel infusion in patients with advanced malignancies, abstract. Proc Am Soc Clin Oncol 14: 1576, 1995

    Google Scholar 

  15. Georgiadis MS, Russell E, Johnson BE: Prolonging the exposure of human lung cancer cell lines to paclitaxel improves the cytotoxicity, abstract. Proc Am Assoc Cancer Res 35: 2028, 1994

    Google Scholar 

  16. Huber MH, Murphy WK, Hong WK, Hittelman WN: Characterization of taxol cytotoxicity against human non-small-cell lung cancer cell lines, abstract. Proc Am Assoc Cancer Res 34: 2079, 1993

    Google Scholar 

  17. Lopes NM, Adams EG, Pitts TW, Bhuyan BK: Cell kill kinetics and cell cycle effects of taxol on human and hamster ovarian cell lines. Cancer Chemother Pharmacol 32: 235-242, 1993

    Google Scholar 

  18. Alberts DS, Krutzsch M, Wymer J, Liddil J, Dvorakova K, Einspahr J, Running K, Dorr RT: Experimental rationale for 24 hour vs. 3 hour paclitaxel infusion schedules in the treatment of advanced ovarian cancer, abstract. Proc Am Assoc Cancer Res 36: 2164, 1995

    Google Scholar 

  19. Seidman AD, Hochhauser D, Gollub M, Edelman B, Yao TJ, Hudis CA, Francis P, Fennelly D, Gilewski TA, Moynahan ME, Currie V, O'Donaghue M, Baselga J, Tong W, Salvaggio R, Auguste L, Spriggs D, Norton L: Ninety-six hour paclitaxel infusion after progression during short taxane exposure: A phase II pharmacokinetic and pharmacodynamic study in metastatic breast cancer. J Clin Oncol 14: 1877-1884, 1996

    Google Scholar 

  20. Chang AY, Bores L, Garrow G, Asbury R: Paclitaxel by 3-hour infusion followed by 96-hour infusion on failure in patients with refractory malignant disease. Sem in Oncol 22(suppl 6): 124-127, 1995

    Google Scholar 

  21. Younes A, Ayoub JP, Hagemeister FB, McLaughlin P, Sarris A, Rodriguez MA, Swan F, Romaguera JE, Martin J, Cabanillas F: No effect of 96-hour paclitaxel infusion in patients with relapsed non-Hodgkin's lymphoma refractory to a 3-hour infusion schedule. J Clin Oncol 14: 543-548, 1996

    Google Scholar 

  22. Eisenhauer EA, ten Bokkel Huinink W, Swenerton KD: European-Canadian randomized trial of paclitaxel in relapsed ovarian cancer: high-dose versus low-dose and long versus short duration. J Clin Oncol 12: 2654-2666, 1994

    Google Scholar 

  23. Winer E, Berry D, Duggan D, Henderson IC, Cirrincione C, Cooper R, Norton L, Cancer and Leukemia Group B: Failure of higher dose paclitaxel to improve outcome in patients with metastatic breast cancer - results from CALGB 9342. Proc. ASCO Vol 17: A388, 1998

  24. Mamounas E, Brown A, Smith R, Lembersky B, Fisher B, Wicherham DL, Wolmark N, Atkins J, Shibata H, Baez L, DeFusco P, Davila E, Thirlwell M, Bearden S, Tipping S, Scholnik A, NSABP Operations and Biostatistical Center: Effect of taxol duration of infusion in advanced breast cancer (ABC): Results from NSABP B-26 trial comparing 3-to 24-hour infusion of high-dose taxol. Proc. ASCO Vol 17: A389, 1998

  25. Holmes FA, Valero V, Buzdar AU, Booser DJ, Winn R, Tolcher A, Seidman A, Goodwin W, Bearden J, Baysinger L, Hortobagyi GN, Arbuck SA: Final results: randomized phase III trial of paclitaxel by 3-hour versus 96-hour infusion in patients (PT) with metastatic breast cancer (MBC). The long and short of it. Proc. ASCO Vol 17: A426, 1998

Download references

Author information

Authors and Affiliations

Authors

Rights and permissions

Reprints and permissions

About this article

Cite this article

Shade, R.J., Pisters, K.M., Huber, M.H. et al. Phase I study of paclitaxel administered by ten-day continuous infusion. Invest New Drugs 16, 237–243 (1998). https://doi.org/10.1023/A:1006157226693

Download citation

  • Issue Date:

  • DOI: https://doi.org/10.1023/A:1006157226693

Navigation